Clinical service

Autoinflammatory and Autoimmunity Syndromes Panels DNA Testing

A physician-led service pathway designed around appropriate screening and clinical context.

Stem Cell Regeneration CenterBangkok, Thailand
Gloved laboratory professional preparing a blood sample beside a centrifuge for Stem Cell Treatment for Primary Sclerosing Cholangitis ( PSC ).
Published

The Regen Center offers Autoinflammatory and Autoimmunity Syndromes DNA test to analyze genes that are associated with autoinflammatory and autoimmune diseases. Autoinflammatory disorders are mainly characterized by systemic inflammation due to incorrect activation of an protective immune response.Β  Alternatively, autoimmune diseases are usually caused by some defects in adaptive immunity that over time leads to a loss of self-tolerance. Autoinflammatory & Autoimmune diseases both share similar symptom manifestations including self-directed inflammation in the absence of a known cause.

Primary DNA Test Panels for Autoinflammatory and Autoimmunity Syndromes include:

  • ACP5
  • ADA
  • ADA2
  • ADAM17
  • ADAR
  • AICDA
  • AIRE
  • ANKZF1
  • AP3B1
  • ARPC1B
  • ASAH1
  • BACH2
  • BLOC1S6
  • BTK
  • C17orf62
  • CARD14
  • CARD8
  • CASP10
  • CASP8
  • CCBE1
  • CD27
  • CD3G
  • CD40
  • CD40LG
  • COPA
  • CR2
  • CTLA4
  • CYBA
  • CYBB
  • DCLRE1C
  • DDX58
  • DEF6
  • DKC1
  • DNASE1L3
  • DNASE2
  • DOCK8
  • DSG1
  • DUOX2
  • ELANE
  • FADD
  • FAS
  • FASLG
  • FCHO1
  • FOXP3
  • G6PC3
  • ICOS
  • IFIH1
  • IL10
  • IL10RA
  • IL10RB
  • IL1RN
  • IL21
  • IL21R
  • IL2RA
  • IL2RB
  • IL2RG
  • IL36RN
  • IRF2BP2
  • ITCH
  • ITGAM
  • ITGB2
  • ITK
  • JAK1
  • LIG4
  • LPIN2
  • LRBA
  • LYN
  • LYST
  • MAGT1
  • MEFV
  • MVK
  • NCF2
  • NCF4
  • NFAT5
  • NFKB1
  • NFKB2
  • NFKBIA
  • NLRC4
  • NLRP1
  • NLRP12
  • NLRP3
  • NOD2
  • OAS1
  • ORAI1
  • OTULIN
  • PEPD
  • PIK3CD
  • PIK3R1
  • PLCG2
  • PNP
  • POLA1
  • POMP
  • PRF1
  • PRKCD
  • PSMA3
  • PSMB4
  • PSMB8
  • PSMG2
  • PSTPIP1
  • RAB27A
  • RAC2
  • RAG1
  • RAG2
  • RASGRP1
  • RBCK1
  • RFX5
  • RFXANK
  • RFXAP
  • RIPK1
  • RMRP
  • RNASEH2A
  • RNASEH2B
  • RNASEH2C
  • RNF31
  • RTEL1
  • SAMHD1
  • SCO2
  • SH2D1A
  • SH3BP2
  • SI
  • SIAE
  • SKIV2L
  • SLC29A3
  • SLC37A4
  • SLC7A7
  • STAT1
  • STAT3
  • STAT4
  • STAT5B
  • STIM1
  • STX11
  • STXBP2
  • TBX1
  • TGFB1
  • TGFBR1
  • TGFBR2
  • TMEM173
  • TNFAIP3
  • TNFRSF11A
  • TNFRSF13B
  • TNFRSF13C
  • TNFRSF1A
  • TNFRSF6B
  • TNFSF12
  • TOP2B
  • TPP2
  • TREX1
  • TRNT1
  • TTC7A
  • UNC13D
  • UNG
  • WAS
  • XIAP
  • ZAP70
  • ZNF341

DNA swab collection concept, unverified draft for editorial review

Optional

Additional panels for other autoinflammatory disordersΒ  caused by defects in adaptive immunity leading to loss of self-tolerance.

Autoimmune diseases and autoinflammatory diagnosis often clinical manifestations and cross-over between these disease groups has been recognized. Both types of conditions result in self-directed inflammation and recent research suggests considerable overlapping of molecular pathways that are involved in both.

  • AIRE
  • AP3B1
  • BLOC1S6
  • CASP10
  • CASP8
  • CD27
  • CR2
  • FADD
  • FAS
  • FASLG
  • IL21R
  • ITCH
  • ITK
  • LYST
  • MAGT1
  • NFKB2
  • NFKBIA
  • ORAI1
  • PNP
  • PRF1
  • PRKCD
  • RAB27A
  • RAC2
  • RFX5
  • RFXANK
  • RFXAP
  • RMRP
  • SLC7A7
  • STAT5B
  • STX11
  • TBX1
  • TNFRSF13B
  • TNFRSF13C
  • TNFSF12
  • TPP2
  • UNC13D
  • UNG

Published Clinical Citations

[1] ^ Ciccarelli, F., De Martinis, M., & Ginaldi, L. (2014). An update on autoinflammatory diseases. Current medicinal chemistry, 21(3), 261–269.https://doi.org/10.2174/09298673113206660303

[2] ^ Arakelyan A, Nersisyan L, Poghosyan D, Khondkaryan L, Hakobyan A, LΓΆffler-Wirth H, Melanitou E, Binder H. Autoimmunity and autoinflammation: A systems view on signaling pathway dysregulation profiles. PLoS One. 2017 Nov 3;12(11):e0187572. doi: 10.1371/journal.pone.0187572. PMID: 29099860; PMCID: PMC5669448https://pubmed.ncbi.nlm.nih.gov/29099860/

Private eligibility review

Clarity begins with your medical records.

Send your diagnosis, recent imaging and relevant records. Our clinical team will determine whether a confidential evaluation is appropriate before treatment options are discussed.

Request evaluation
01Send recordsDiagnosis and recent clinical history
02Clinical reviewIndividual suitability assessment
03Next stepsA private response from our team